ArticleHeliyon2024

A randomized, double-blinded, placebo-controlled, single-center, comparative study evaluating Phaseolean® safety and efficacy in overweight/obese participants.

Shashi Chandrama Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.